Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.445 AUD | -1.11% | -8.25% | +28.99% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.99% | 354M | B- | ||
+29.77% | 49.18B | B- | ||
+1.00% | 42.11B | B | ||
+50.47% | 40.37B | A | ||
-5.26% | 28.85B | C | ||
+13.68% | 26.09B | B- | ||
-22.99% | 18.71B | B | ||
+8.22% | 13.26B | B+ | ||
+32.41% | 12.32B | C+ | ||
-1.62% | 11.99B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IMM Stock
- Ratings Immutep Limited